Faro raised $37 million in a Series B round to accelerate AI-enabled clinical trial execution, focusing on reducing time and cost once programs move into the trial phase. The company aims to build tooling that helps sponsors run studies faster by better managing key operational steps where delays often compound. The funding signals investor confidence in AI approaches that target the late-stage bottlenecks of development rather than upstream molecule design alone. As competitive pressure grows to improve trial efficiency, Faro’s strategy aligns with broader demand for analytics and automation that can be deployed directly in clinical operations and monitoring workflows.